Acurx enrolls first patient in PATHFINDER Phase 2 trial of ibezapolstat for recurrent C. difficile infection

Bitget2026/09/29 12:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Acurx enrolled the first patient in PATHFINDER, a Phase 2 study of ibezapolstat in multiply recurrent C. difficile infection.
No results have been presented yet; the trial will evaluate whether treatment can clear infection and reduce repeat episodes over follow-up.
The study is designed to support an FDA filing strategy that could rely on a single Phase 3 trial, if supported by total data.
Management also reiterated plans for the larger Phase 3 ASPIRE trial versus vancomycin, subject to funding availability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY58703) on September 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Acurx enrolls first patient in PATHFINDER Phase 2 trial of ibezapolstat for recurrent C. difficile infection

You may also like

Crypto prices